138 related articles for article (PubMed ID: 38716613)
1. The Potential Role of Urinary Microbiota in Bladder Carcinogenesis: A Systematic Review.
Ghabousian A; Shafigh A; Tayebi S; Salehi-Pourmehr H; Mostafaei H; Lemberger U; Mori K; Sadeghi-Ghyassi F; Hassanzadeh H; Hajebrahimi S; Shariat SF
Urol J; 2024 Jun; 21(4):208-220. PubMed ID: 38716613
[TBL] [Abstract][Full Text] [Related]
2. Investigating the association between the urinary microbiome and bladder cancer: An exploratory study.
Hussein AA; Elsayed AS; Durrani M; Jing Z; Iqbal U; Gomez EC; Singh PK; Liu S; Smith G; Tang L; Guru KA
Urol Oncol; 2021 Jun; 39(6):370.e9-370.e19. PubMed ID: 33436328
[TBL] [Abstract][Full Text] [Related]
3. The Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage.
Oresta B; Braga D; Lazzeri M; Frego N; Saita A; Faccani C; Fasulo V; Colombo P; Guazzoni G; Hurle R; Rescigno M
J Urol; 2021 Jan; 205(1):86-93. PubMed ID: 32856979
[TBL] [Abstract][Full Text] [Related]
4. Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China.
Wu P; Zhang G; Zhao J; Chen J; Chen Y; Huang W; Zhong J; Zeng J
Front Cell Infect Microbiol; 2018; 8():167. PubMed ID: 29904624
[TBL] [Abstract][Full Text] [Related]
5. The bladder microbiota is not significantly altered by intravesical BCG therapy.
Heidrich V; Mariotti ACH; Inoue LT; Coser EM; Dos Santos EX; Dos Santos HDB; Asprino PF; Bettoni F; Costa GAP; Bastos DA; Jardim DL; Arap MA; Camargo AA
Urol Oncol; 2024 Jan; 42(1):22.e13-22.e21. PubMed ID: 38030469
[TBL] [Abstract][Full Text] [Related]
6. Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon-degrading Bacteria Among Bladder Cancer Patients.
Bukavina L; Isali I; Ginwala R; Sindhani M; Calaway A; Magee D; Miron B; Correa A; Kutikov A; Zibelman M; Ghannoum M; Retuerto M; Ponsky L; Markt S; Uzzo R; Abbosh P
Eur Urol Oncol; 2023 Apr; 6(2):190-203. PubMed ID: 36868921
[TBL] [Abstract][Full Text] [Related]
7. The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M.
Sun JX; Xia QD; Zhong XY; Liu Z; Wang SG
Front Cell Infect Microbiol; 2023; 13():1182322. PubMed ID: 37351184
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer is associated with decreased urinary microbiota diversity and alterations in microbial community composition.
Hrbáček J; Tláskal V; Čermák P; Hanáček V; Zachoval R
Urol Oncol; 2023 Feb; 41(2):107.e15-107.e22. PubMed ID: 36402713
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. The urinary microbiome associated with bladder cancer.
Bučević Popović V; Šitum M; Chow CT; Chan LS; Roje B; Terzić J
Sci Rep; 2018 Aug; 8(1):12157. PubMed ID: 30108246
[TBL] [Abstract][Full Text] [Related]
11. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
12. Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study.
Chipollini J; Wright JR; Nwanosike H; Kepler CY; Batai K; Lee BR; Spiess PE; Stewart DB; Lamendella R
Urol Oncol; 2020 Jul; 38(7):615-621. PubMed ID: 32414567
[TBL] [Abstract][Full Text] [Related]
13. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project.
Hurle R; Casale P; Saita A; Colombo P; Elefante GM; Lughezzani G; Fasulo V; Paciotti M; Domanico L; Bevilacqua G; Maffei D; Diana P; Frego N; Sandri MT; Maura F; Morenghi E; Buffi NM; Guazzoni G; Lazzeri M
World J Urol; 2020 Sep; 38(9):2215-2220. PubMed ID: 31691083
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer.
Grobet-Jeandin E; Lenfant L; Mir C; Giannarini G; Alcaraz A; Albersen M; Breda A; Briganti A; Rouprêt M; Seisen T;
Eur Urol Oncol; 2023 Jun; 6(3):251-262. PubMed ID: 36906510
[TBL] [Abstract][Full Text] [Related]
15. Does the urinary microbiome profile change after treatment of bladder cancer?
Hussein AA; Bhat TA; Jing Z; Gomez EC; Wasay MA; Singh PK; Liu S; Smith G; Guru KA
World J Urol; 2023 Dec; 41(12):3593-3598. PubMed ID: 37796319
[TBL] [Abstract][Full Text] [Related]
16. Nested quantitative PCR approach for urinary cell-free EZH2 mRNA and its potential clinical application in bladder cancer.
Zhang X; Zhang Y; Liu X; Liu T; Li P; Du L; Yang Y; Wang L; Wang C
Int J Cancer; 2016 Oct; 139(8):1830-8. PubMed ID: 27300769
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries.
Rahman ZA; Hidayatullah F; Lim J; Hakim L
Arch Ital Urol Androl; 2024 Feb; 96(1):12154. PubMed ID: 38363237
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
[TBL] [Abstract][Full Text] [Related]
19. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
20. Bladder cancer invasion predictability based on preoperative neutrophil-lymphocyte ratio.
Kaynar M; Yıldırım ME; Badem H; Caviş M; Tekinarslan E; Istanbulluoğlu MO; Karataş ÖF; Çimentepe E
Tumour Biol; 2014 Jul; 35(7):6601-5. PubMed ID: 24696263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
